Extended Data Fig. 7: Senolysis as a novel treatment concept in COVID-19 in additional animal models.
From: Virus-induced senescence is a driver and therapeutic target in COVID-19
a, Daily body weight assessment of dwarf hamsters and K18-hACE2 mice infected with SARS-CoV-2 (or uninfected healthy controls), and subsequently treated with senolytics as in b–e e and Fig. 5b–e. Dwarf hamsters: n = 5 each for SARS-CoV-2-infected solvent-only-, navitoclax- or D/Q-treated; n = 2 for the healthy control group. K18-hACE2-transgenic mice: n = 5 for solvent, navitoclax, and D/Q; n = 4 for fisetin. b, Survival rate of K18-hACE2-transgenic mice on day 6d after infection with SARS-CoV-2 and subsequent senolytic treatment as in a. c, Histological scoring of H/E-stained lung tissue of K18-hACE2 mice as in a and b. d, Viral load in hamster and mouse tissues on day 6 (mouse, as in a–c), day 7 (golden hamster, as in Fig. 5a and Extended Data Fig 6), and day 4 (dwarf hamster, as in Fig. 5b-e) after infection. e, IHA of senescence markers (p16INK4A, H3K9me3) and lipofuscin-staining in lung specimens of K18-hACE2-transgenic mice as in a–d. All bar plots in this figure show mean results + s.d. with individual values as dots.
